Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-MESO CAR T cells
- Development stage
- Unknown
- Lead developer
- UTC Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
anti-MESO CAR T cells (also known as mRNA CAR-mesothelin T cells or CARTmeso cells) is an investigational autologous cell therapy developed by Ruijin Hospital. It consists of patient-derived T cells engineered via mRNA electroporation to transiently express a chimeric antigen receptor (CAR) targeting mesothelin (MSLN), a protein overexpressed in various solid tumors. The CAR construct includes CD3-ζ and 4-1BB co-stimulatory domains. Unlike traditional CAR-T therapies that use viral vectors for stable integration, the mRNA-based approach results in transient CAR expression, which is intended to mitigate potential off-target toxicities. It is currently being evaluated in Phase I clinical trials (e.g., the Amaretto study, NCT04981691) for the treatment of refractory advanced solid tumors, including pancreatic cancer, ovarian cancer, malignant mesothelioma, gastric cancer, and bowel cancer.
- Other names
- mRNA CAR-mesothelin T cellsanti-MESO CAR-T cellsmRNA-engineered anti-mesothelin CAR-T cells
02
Targets
Mesothelin
Beyond the preview
Go deeper on anti-MESO CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-MESO CAR T cells.